Patents by Inventor Elizabeth K. John

Elizabeth K. John has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • High dose radionuclide complexes for bone marrow treatment
    Patent number: 7696331
    Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
    Type: Grant
    Filed: June 19, 2008
    Date of Patent: April 13, 2010
    Assignee: Poniard Pharmaceuticals, Inc.
    Inventors: Alan R. Fritzberg, Paul G. Abrams, Lauren Marie Tatalick, Kent R. Thoelke, James Kyle Bryan, Mark D. Hylarides, Elizabeth K. John
  • HIGH DOSE RADIONUCLIDE COMPLEXES FOR BONE MARROW TREATMENT
    Publication number: 20090136419
    Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
    Type: Application
    Filed: June 19, 2008
    Publication date: May 28, 2009
    Inventors: Alan R. Fritzberg, Paul G. Abrams, Lauren Marie Tatalick, Kent R. Thoelke, James Kyle Bryan, Mark D. Hylarides, Elizabeth K. John
  • Treatment of bone-associated cancers
    Patent number: 7408046
    Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
    Type: Grant
    Filed: June 30, 2004
    Date of Patent: August 5, 2008
    Assignee: Poniard Pharmaceuticals, Inc.
    Inventors: Alan R. Fritzberg, Paul G. Abrams, Lauren Marie Tatalick, Kent R. Thoelke, James Kyle Bryan, Mark D. Hylarides, Elizabeth K. John
  • High dose radionuclide complexes for bone marrow suppression
    Patent number: 7378077
    Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
    Type: Grant
    Filed: July 12, 2006
    Date of Patent: May 27, 2008
    Assignee: Poniard Pharmaceuticals, Inc.
    Inventors: Alan R. Fritzberg, Lauren Marie Tatalick, Kent R. Thoelke, James Kyle Bryan, Mark D. Hylarides, Elizabeth K. John
  • High dose radionuclide complexes for bone marrow suppression
    Patent number: 7097823
    Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
    Type: Grant
    Filed: February 23, 2004
    Date of Patent: August 29, 2006
    Assignee: NEORX Corporation
    Inventors: Alan R. Fritzberg, Paul G. Abrams, Lauren Marie Tatalick, Kent R. Thoelke, James Kyle Bryan, Mark D. Hylarides, Elizabeth K. John
  • High dose radionuclide complexes for bone marrow suppression
    Patent number: 7070759
    Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
    Type: Grant
    Filed: January 24, 2005
    Date of Patent: July 4, 2006
    Assignee: NeoRx Corporation
    Inventors: Alan R. Fritzberg, Paul G. Abrams, Lauren Marie Tatalick, Kent R. Thoelke, James Kyle Bryan, Mark D. Hylarides, Elizabeth K. John
  • High dose radionuclide complexes for bone marrow suppression
    Patent number: 6767531
    Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
    Type: Grant
    Filed: December 11, 2001
    Date of Patent: July 27, 2004
    Assignee: NeoRx Corporation
    Inventors: Alan R. Fritzberg, Paul G. Abrams, Lauren Marie Tatalick, Kent R. Thoelke, James Kyle Bryan, Mark D. Hylarides, Elizabeth K. John
  • High dose radionuclide complexes for bone marrow suppression
    Publication number: 20020176818
    Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
    Type: Application
    Filed: December 11, 2001
    Publication date: November 28, 2002
    Inventors: Alan R. Fritzberg, Paul G. Abrams, Lauren Marie Tatalick, Kent R. Thoelke, James Kyle Bryan, Mark D. Hylarides, Elizabeth K. John